But the value of electrodiagnostic (EDX) study grades as a prognostic indicator of clinical results after Carpal Tunnel Release (CTR) remains controversial. Electroneuromyography (ENMG) is the gold standard for evaluating the function of the median nerve in patients with clinical manifestations of CTS. When symptoms are mild, provocative maneuvers (such as Tinel’s and Phalen’s test) may elicit CTS symptoms and require further examinations however, when symptoms are severe (weakness, sensory deficits, or limitations in daily living activities), studies on nerve conduction are recommended. Its diagnosis is based on clinical data, questionnaires, and neurological examinations. CTS is the most common and well-known cause of peripheral nerve compression, with an incidence ranging from 50 to 150 cases in 100,000 inhabitants. The repetitive stress causes chronic inflammation of the connective tissue, increasing the pressure inside the canal of the wrist, and resulting in venous hyperemia and edema which leads to ischemic damage of the nerve. It is caused by the compression and traction of the median nerve at the level of the carpal tunnel. Mean values in the Boston Carpal Tunnel Questionnaire significantly decreased in both groups.Ĭonclusion: Nucleo CMP Forte™ in combination with ES contributes to a more pronounced regression of patients' complaints, clinical manifestations, severity, and neurophysiological indicators in mild-to-moderate CTS.Ĭarpal Tunnel Syndrome (CTS) is a complex disorder with sensitive, motor, and autonomic symptoms. Positive Tinel test was revealed in 52.4% of patients after the first and 76.2% after the second stage in the exploratory group, versus 43.8% in the control group. Results: In the exploratory group, the complete restoration of pain sensitivity was achieved by 17.1% of patients and the narrowing of the existing zone of hypesthesia by 74.3%. The combination treatment included two stages: Nucleo CMP Forte™ and ES for ten days (stage one), and Nucleo CMP Forte™ as monotherapy (stage two) for ten days. Patients were randomized to receive the exploratory treatment (Nucleo CMP Forte™ and ES) or single ES treatment for ten days. Methods: This open-label, randomized, controlled study involved 60 patients with CTS at the Azerbaijan Medical University (Baku, Azerbaijan) and Research Institute of Medical Rehabilitation between 20 years. The objective of the study was to evaluate the effectiveness of a novel product containing uridine and cytidine monophosphate (Nucleo CMP Forte™) in combination with ES for the treatment of CTS. To date, none of the studies have determined the optimal combination of pyrimidine nucleotides and electrical stimulation (ES) in CTS patients. Introduction: Carpal Tunnel Syndrome (CTS) is the most common and best well-known cause of peripheral nerve compression.

Para que es nucleo cmp forte